Bio-Rad Reports Third-Quarter 2026 Financial Results
Key Highlights
- ➤Q3 sales $656.4M, up 0.5% year over year
- ➤Non-GAAP EPS $2.65, up from $2.26
- ➤Clinical Diagnostics sales $401.8M, up 2.7% year over year
- ➤Non-GAAP operating margin expanded to 12.8% from 11.8%
- ➤2026 outlook maintained: currency-neutral revenue down 3.0% to up 0.5%
Expert Statements
Norman Schwartz, Chief Executive Officer of Bio-Rad
“Our third-quarter results reflect the steady progress we have been driving. We returned to currency-neutral revenue growth, led by Clinical Diagnostics and strong demand for our Droplet Digital™ PCR instruments. Excluding restructuring and impairment items, margins expanded, reflecting benefits of our transformation initiatives. The reprioritization of our R&D efforts is yielding new, differentiated products for our customers, and our progress gives us confidence in our 2026 outlook.”
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2026.
Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “Our third-quarter results reflect the steady progress we have been driving. We returned to currency-neutral revenue growth, led by Clinical Diagnostics and strong demand for our Droplet Digital™ PCR instruments. Excluding restructuring and impairment items, margins expanded, reflecting benefits of our transformation initiatives. The reprioritization of our R&D efforts is yielding new, differentiated products for our customers, and our progress gives us confidence in our 2026 outlook.” Financial Results Highlights (In millions, except per share data and percentages)
Get started
Create a free account to read the full story.